ATAbigail R. Tirrell

Abigail R. Tirrell

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Abigail R. Tirrell has a total of 25 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Selecting a chest masculinization plastic surgeon: a survey of transgender patients

    by Abigail R. Tirrell, Brian L. Chang, Idanis M. Perez-Alvarez, Paige K. Dekker, Kevin G. Kim, Kenneth L. Fan, Gabriel Del Corral

    Background Chest masculinization is a commonly performed gender-affirming procedure in transmasculine and non-binary patients and has increased in prevalence in recent years despite continued barriers to surgical care. With the expansion of insurance coverage and trained surgeons, patients at times have the opportunity to be selective in choosing their gender-affirming surgeon. This study aimed to investigate factors that transmasculine individuals consider important when selecting their chest masculinization plastic surgeon. Methods All patients who underwent chest masculinization with a single surgeon between January 2018 and December 2021 were surveyed via an online questionnaire to rate 21 factors associated with surgeon selection. Multiple-choice questions and free text space were included to further clarify patient preferences. Results were analyzed to rate factors in order of importance. Results One hundred three individuals completed the survey, generating a response rate of 49.5%. Average patient age at time of surgery was 27.0 years, and 2.0% of patients had prior gender affirmation surgery (GAS). The top five most important factors were surgeon specialization in GAS, insurance coverage, board certification, number of times surgeon has performed procedure, and availability of Before and After photographs. The five least important factors were age of surgeon, medical publications, availability of YouTube videos, location of training, and surgeon presence on social media. Conclusions Transmasculine patients employ distinct criteria when selecting a chest masculinization gender-affirming plastic surgeon. An improved understanding of these factors informs providers of ways to enhance patient access to information and gender-affirming care. Level of evidence: Not gradable.


  • Open Access

    Bacitracin for Injection Recall: Impact on Immediate Breast Implant Surgical Outcomes

    by Abigail R. Tirrell, Jenna C. Bekeny, Eshetu A. Tefera, David H. Song, Kenneth L. Fan

    Background. Triple-antibiotic irrigation of breast implant pockets is a mainstay of infection prophylaxis in breast reconstruction and augmentation. The recall of bacitracin for injection due to risk of anaphylaxis and nephrotoxicity in January 2020, a staple component of the irrigation solution, has raised concern for worsened postoperative sequelae. This study aimed to investigate pre- and post-recall implant-based breast surgery to analyze the impact of bacitracin in irrigation solutions on infection rates. Methods. All implant-based breast reconstruction or augmentation surgeries from January 2019 to February 2021 were retrospectively reviewed. In a regression discontinuity study design, patients were divided into pre- and post-recall groups. Patient demographics, surgical details, and outcomes including infection rates were collected. Differences in complication rates were compared between groups and with surgical and patient factors. Results. 254 implants in 143 patients met inclusion criteria for this study, with 172 implants placed before recall and 82 placed after recall. Patients in each cohort did not differ in age, BMI, smoking status, or history of breast radiation or capsular contracture ( ). All breast pockets were irrigated with antibiotic solution, most commonly bacitracin, cefazolin, gentamycin, and povidone-iodine before recall (116,67.4%) and cefazolin, gentamycin, and povidone-iodine after recall (59,72.0%). There was no difference in incidence of infection (6.4% vs. 8.5%, ) or cellulitis (3.5% vs. 3.7%, ) before and after recall. Implant infection was associated with smoking history ( ) and increased surgical time ( ). Conclusions. Despite the recent recall of bacitracin from inclusion in breast pocket irrigation solutions, our study demonstrated no detrimental impact on immediate complication rates. This shift in irrigation protocols calls for additional investigations into optimizing antibiotic combinations in solution, as bacitracin is no longer a viable option, to improve surgical outcomes and long-term benefits.


  • Open Access

    P142. PREDICTION OF ADVERSE OUTCOMES FOLLOWING FREE TISSUE TRANSFER USING LACE INDEX FOR THE TREATMENT OF CHRONIC LOWER EXTREMITY WOUNDS

    by Zoe K. Bs Haffner, Areeg A Abu El Hawa, Kunal M. Kirloskar, Connor Bs Lester, Abigail R. Bs Tirrell, Kevin G. Bs Kim, Paige K. Ba Dekker, Jenna C. Bekeny, Kenneth L. Fan, Karen K. Evans

  • Risk Factors for Loss to Follow-Up in the Lower Extremity Limb Salvage Population

    by Banafsheh Sharif-Askary, Elizabeth G. B.S. Zolper, Romina Deldar, Eshetu M.S. Tefera, Abigail R. B.S. Tirrell, Areeg A. B.S. Abu El Hawa, Christopher E. Attinger, Karen K. Evans, Kenneth L. Fan

    Background: Limb salvage for chronic lower extremity wounds requires long-term care best delivered by specialized multidisciplinary centers. This optimizes function, reduces amputation rates, and improves mortality. These centers may be limited to urban/academic settings, making access and appropriate follow-up challenging. Therefore, the authors hypothesize that both system- and patient-related factors put this population at exceedingly high risk for loss to follow-up. Methods: Records were reviewed retrospectively for 200 new patients seen at the Georgetown Center for Wound Healing in 2013. The primary outcome was loss to follow-up, defined as three consecutive missed appointments despite explicit documentation indicating the need for return visits. Demographic, clinical, and geographic data were compared. Multivariate logistic regression analysis for loss to follow-up status controlled for variables found significant in the bivariate analysis. Spatial dependency was evaluated using variograms. Results: Over a 6.5-year-period, 49.5 percent of patients followed were lost to follow-up. Male sex and increased driving distance to the limb salvage center were risk factors for loss to follow-up. Wound-specific characteristics including ankle and knee/thigh location were also associated with higher rates of loss to follow-up. There was no spatial dependency or discrete clustering of at-risk patients. Conclusions: This study is the first of its kind to investigate the demographic and clinical characteristics that predispose chronic lower extremity wound patients to loss to follow-up. These findings inform stakeholders of the high rates of loss to follow-up and support decentralized specialty care, in the form of telemedicine, satellite facilities, and/or dedicated case managers. Future work will focus on targeting vulnerable populations through focused interventions to reduce patient and system burden. CLINICAL QUESTION/LEVEL OF EVIDENCE: Risk, III.


  • Minimizing opioid consumption by eliminating patient‐controlled analgesia after penile inversion vaginoplasty with enhanced recovery after surgery (ERAS) protocol

    by Abigail R. Tirrell, Areeg A. Abu El Hawa, Jenna C. Bekeny, Kenneth L. Fan, Gabriel Del Corral

    Background: Genital‐based gender affirmation surgery is a physically demanding procedure requiring extensive postoperative pain management. However, perioperative opioid use for these procedures is relatively understudied.Objectives: This study analyzes whether intravenous patient‐controlled analgesia (PCA) enhances pain control after penile inversion vaginoplasty (PIV) in the setting of enhanced recovery after surgery (ERAS) protocols, and whether non‐PCA (NCA)‐based regimens could reduce postoperative opioid use.Methods: All patients undergoing PIV with ERAS protocols by a single provider from December 2018 to November 2020 were retrospectively reviewed. Patient demographics, comorbid conditions, pain scores, length of stay (LOS), and opioid usage during their hospitalization were collected. Postoperative opioid use and pain scores were compared between PCA and NCA patient cohorts.Results: A total of 61 patients were included. 30 patients received intravenous PCA postoperatively, and 31 patients used NCA‐based narcotic pain control. All patients underwent ERAS protocol perioperatively. Average patient age was 34.5 years (SD 11.9) in the PCA cohort and 37.6 years (SD 11.9) in the NCA cohort (p = 0.242). Average total postoperative opioid use during hospital stay was reduced by 53.7% in the NCA cohort, with an average use of 501.6 morphine milligram equivalents (MME) (SD 410.3) among PCA patients and an average use of 232.0 MME (SD 216.5) among NCA patients (p = 0.003). Daily average pain scores for postoperative days 1 to 6 did not differ between the PCA and NCA patient groups (p > 0.05). Average hospital LOS was shorter among NCA patients, 6.2 days (SD 1.0) versus 7.3 days (SD 1.4), respectively, (p < 0.001).Discussion: In combination with an ERAS non‐narcotic pain control protocol, it may be possible to reduce opioid use by more than 50% and shorten length of postoperative hospital stay among patients by implementing NCA pain management protocols.Conclusion: Minimizing postoperative opioid consumption after PIV will benefit patients and their sustained well‐being.